- Scorpius Holdings, Inc. has announced a collaboration with KaloCyte to optimise manufacturing processes for ErythroMer, a bio-inspired artificial red blood cell.
- The companies are also exploring a commercial-scale manufacturing agreement for the therapy, designed for cases of life-threatening blood loss.
Scorpius Holdings, Inc. , a contract development and manufacturing organisation (CDMO), has partnered with KaloCyte, a pre-clinical biotech therapeutic startup company. Scorpius will enhance manufacturing efficiencies for KaloCyte’s lead candidate, ErythroMer, a dried artificial red blood cell addressing life-threatening blood loss in emergencies where traditional blood supplies are unavailable or unsuitable.
This collaboration also evaluates the potential for a commercial-scale manufacturing agreement, reinforcing Scorpius’ position as a trusted biomanufacturing partner. Jeff Wolf, CEO of Scorpius, stated, “By refining manufacturing processes for KaloCyte’s lead candidate, we are poised to accelerate its journey toward clinical success and expand its reach to patients who need it most.”
KaloCyte’s President and CEO, Elaine Haynes, highlighted Scorpius’ alignment with federal biodefense funding and its growing production capabilities as key factors in the collaboration.
Based in San Antonio, Texas, Scorpius offers a range of services, including analytical testing, process development, and cGMP clinical manufacturing. This partnership reflects its commitment to advancing biotech innovations from early development to clinical application.